Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/885306/000119312510055023/d10k.htm
March 2017
February 2017
February 2017
February 2017
January 2017
December 2016
October 2016
October 2016
September 2016
July 2016
Exhibit 99.1
Contact:
Scott Solomon
Vice President
Sharon Merrill Associates, Inc.
617-542-5300
cyno@investorrelations.com
Cynosure Reports Fourth-Quarter and Full-Year 2009 Financial Results
Company Achieves Targeted 09 Operating Expense Savings of $18 Million
Westford, Mass., February 9, 2010 Cynosure, Inc. (NASDAQ: CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced financial results for the three and 12 months ended December 31, 2009.
Fourth-Quarter 2009 Financial Results
Revenues for the three months ended December 31, 2009 were $19.3 million, compared with $25.5 million for the same period of 2008 and $17.9 million for the third quarter of 2009. The decrease in revenues from the fourth quarter of 2008 reflected the continued effects of the global economic slowdown on the aesthetic laser industry. Access to credit remains a significant hurdle for many practitioners seeking to make aesthetic capital equipment purchases.
Financial results for the three months ended December 31, 2009 included: a non-cash tax charge of $10.4 million to establish a valuation allowance against the companys U.S. deferred tax assets, primarily consisting of temporary differences; and a $2.1 million non-cash charge related to an inventory write-down of an earlier-generation product. The write-down resulted in part from rapid customer adoption of Cynosures newer-generation products, coupled with the downturn in the overall aesthetic laser market.
Gross profit for the fourth quarter of 2009 was 43.9% of total revenues, compared with 60.5% for the same period of 2008 and 58.4% for the third quarter of 2009. Excluding the $2.1 million inventory write-down, gross profit for the fourth quarter of 2009 was 54.7% of total revenues. In addition to the write-down, the decrease in gross profit from the sequential and year-over-year periods reflected a higher percentage of laser revenue from international markets, where sales prices tend to be lower than in the U.S. and Canada, and a decline in average selling prices due to overall market conditions.
Including the charge for the valuation allowance against deferred tax assets and the inventory write-down, the net loss for the fourth quarter of 2009 was $14.5 million, or $1.14 per basic and diluted share. This compared with a net loss of $2.5 million, or $0.20 per basic and diluted share, for the fourth quarter of 2008.
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/885306/000119312510055023/d10k.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Cynosure Inc.
Cynosure Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2010 10-K Annual Report includes:
Material Contracts, Statements, Certifications & more
Cynosure Inc provided additional information to their SEC Filing as exhibits
Ticker: CYNO
CIK: 885306
Form Type: 10-K Annual Report
Accession Number: 0001193125-10-055023
Submitted to the SEC: Fri Mar 12 2010 1:05:57 PM EST
Accepted by the SEC: Fri Mar 12 2010
Period: Thursday, December 31, 2009
Industry: Electromedical And Electrotherapeutic Apparatus